Works cited document for "Effective Management of Acute and Chronic Pain with Opioid Analgesics, 2nd Edition"
Effective Management of Acute and Chronic Pain with Opioid Analgesics, 2nd Edition _ _________________
Works Cited 1. Centers for Disease Control & Prevention. Understanding the epidemic. 2019. https://www.cdc.gov/drugoverdose/epidemic/index.html 2. Centers for Disease Control & Prevention. Prescription painkiller overdoses in the US. Vital Signs. Updated August 22, 2023. https:// www.cdc.gov/drugoverdose/deaths/index.html 3. Centers for Disease Control & Prevention. Opioid overdose: Understanding the epidemic. 2021. https://www.cdc.gov/drugoverdose/ images/3-waves-2019.PNG 4. Dydyk AM, Jain NK, Gupta M. Opioid use disorder. Updated January 17, 2024. StatPearls. https://www.ncbi.nlm.nih.gov/books/ NBK553166/ 5. Centers for Disease Control & Prevention. Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morbidity and Mortality Weekly Report. 2011;60(43):1487-1492. 6. Centers for Disease Control & Prevention. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. December 28, 2020. https://emergency.cdc.gov/han/2020/ han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20 Public&deliveryName=USCDC_511-DM44961 7. Centers for Disease Control & Prevention. 2018 annual surveillance report of drug-related risks and outcomes--United States surveillance special report 2. August 31, 2018. https://www.cdc.gov/rxawareness/pdf/articles/TA-T3D2-English_MatteArticle_Release_508.pdf 8. Centers for Disease Control & Prevention. 12 month-ending provisional number of drug overdose deaths. December 28, 2020. https:// www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm 9. Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: A systematic review and meta-analysis. JAMA 2018;320(23):2448-2460. 10. Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA 2018;319(9):872-882. 11. Covington EC. Anticonvulsants for neuropathic pain and detoxification. Cleveland Clin J Med 1998;65 Suppl 1:SI21-29. 12. U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force report: Updates, gaps, inconsistencies, and recommendations. 2019. https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html 13. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-130. 14. Lee WM. Acetaminophen (APAP) hepatotoxicity—Isn’t it time for APAP to go away? J Hepatol 2017;20(17):32148-32147. 15. Food and Drug Administration. FDA briefing document: Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, April 24 and 25, 2018. 16. Brown, T. CV safety of celecoxib similar to naproxen, ibuprofen, FDA panels say. Medscape. 2018. Accessed October 28, 2024. https:// www.medscape.com/viewarticle/895722 17. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-130. 18. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Datab Systemat Rev 2017;1:CD007393. 19. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Rongwei F, Kansagara D, Chow R. Cannabis-based products for chronic pain: A systematic review. Ann Int Med 2002, Jun 7;175(8). 20. Johal H, Devji T, Chang Y, Simone J, Vannabouathong C, Bhandari M. Cannabinoids in chronic non-cancer pain: A systematic review and meta-analysis. Clin Med Insights Arthritis Musculoskelet Disord. 2020 Feb 19;13:1179544120906461. doi: 10.1177/1179544120906461. PMID: 32127750; PMCID: PMC7031792. 21. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA 2015;313(24):2474-2483. 22. Shover CL et al. Proc Natl Acad Sci USA 2019;116:12624-12626. 23. Adel Y, Alexander SPH. Neuromolecular mechanisms of cannabis action. Adv Exp Med Biol 2021;1264:15-28. 24. Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management. American Society of Regional Anesthesia and Pain Medicine, American Academy of Pain Medicine, and American Society of Anesthesiologists. Reg. Anesth Pain Med 2018;43(5):456-466. 25. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008;24(6):479-496. 26. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiol. 2006;104(3):570-587. 27. Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: A systematic review and meta-analysis. JAMA 2018;320(23):2448-2460.
28. US Department of Health and Human Services. FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. 2017. 29. Substance Abuse and Mental Health Services Administration. 2022 national survey on drug use and health. 2022 NDSUH detailed tables. Table 1.110A. 2023. 30. Stimulant overdose. (2024, November 7). Overdose Prevention. https://www.cdc.gov/overdose-prevention/about/stimulant-overdose.html 31. 31. Brandow AM, Carroll CP, Creary S, Edwards-Elliot R, Glassberg J, Hurley RW, Kutlar A, Seisa M, Stinson J, Strouse JJ, Yusuf F, Zempsky W, Lang E. American Society of Hematology 2020 guidelines for sickle cell disease management of acute and chronic pain. Blood Adv 2020;48:241-248. 32. Carroll CP. Opioid treatment for acute and chronic pain in patients with sickle cell disease. Neurosci Lett 2020, Jan 1;714:134534. doi: 10.1016/j.neulet 33. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. 2018. HHS Publication No SMA 18-5068, NSDUH Series H-53 34. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. 35. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8(7):573-582. 36. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Int Med 2017;167(5):293-301. 37. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65(1):1-49. 38. Lee TH. Zero pain is not the goal. Jama. 2016;315(15):1575-1577. 39. Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504. 40. Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid prescribing at hospital discharge contributes to chronic opioid use. Journal of general internal medicine. 2016;31(5):478-485. 41. Bateman BT, Franklin JM, Bykov K, et al. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naive women. Am J Obstet Gynecol. 2016;215(3):353 e351-353 e318. 42. Johnson SP, Chung KC, Zhong L, et al. Risk of prolonged opioid use among opioid-naive patients following common hand surgery procedures. The Journal of hand surgery. 2016;41(10):947-957 e943. 43. Ltd, R. a. M. (n.d.). U.S. Outpatient Surgical Procedures Market by Surgical Procedure Type, Patient Care Setting - US Forecast to 2023. Research and Markets Ltd 2024. https://www.researchandmarkets.com/reports/4746620/us-outpatient-surgical-procedures-market- by?srsltid=AfmBOorDcHf7MPg3_gN_ZjbWsEQc5cHcW1hXGco5xpZiv842F0jbb0lG 44. American Pain Society. Management of acute pain and chronic noncancer pain. Accessed Oct 29, 2018. http://americanpainsociety.org/ education/enduring-materials 45. Frogner BK, Harwood K, Andrilla CHA, Schwartz M, Pines JM. Physical therapy as the first point of care to treat low back pain: An instrumental variables approach to estimate impact on opioid prescription, healthcare utilization, and costs. Health Serv Res 2018;53(6):4629-4646. 46. Centers for Disease Control & Prevention. 2018. Module 2: Treating pain without opioids. Course number WB2859. https://www.cdc. gov/drugoverdose/training/nonopioid 47. Goodman CW, Brett AS. Gabapentin and pregabalin for pain: Is increased prescribing a cause for concern? N Engl J Med 2017;377(5):411- 414. 48. Mathieson S, Maher CG, McLachlan AJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med 2017;376(12):1111-1120. 49. Blendon RJ, Benson JM. The public and the opioid-abuse epidemic. N Engl J Med 2018;378(5):407-411. 50. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156(4):569-576. 51. Wu CL, Raja SN. Treatment of acute postoperative pain. Lancet 2011;377(9784):2215-2225. 52. Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: A randomized clinical trial. JAMA 2017;318(17):1661-1667. 53. Poonai N, Datoo N, Ali S, et al. Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: A randomized controlled trial. CMAJ 2017;189(40):E1252-E1258. 54. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Int Med 2010;170(22):1968-1976. 55. Gil JA, Gunaseelan V, DeFroda SF, Brummett CM, Bedi A, Waljee JF. Risk of prolonged opioid use among opioid-naive patients after common shoulder arthroscopy procedures. Am J Sports Med 2019;47(5):1043-1050.
56. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Int Med 2015;175(4):608-615. 57. Michigan Opioid Prescribing Engagement Network. Opioid prescribing recommendations for surgery. 2019. https://opioidprescribing. info/ 58. Kim N, Matzon JL, Abboudi J, et al. A prospective evaluation of opioid utilization after upper-extremity surgical procedures: Identifying consumption patterns and determining prescribing guidelines. J Bone Joint Surg Am 2016;98(20):e89. 59. Chu J, Farmer B, Ginsburg B, et al. New York City emergency department discharge opioid prescribing guidelines. 2013. https://www1. nyc.gov/site/doh/providers/health-topics/opioid-prescribing-resources-for-emergency-departments.page 60. Thorson D, Biewen P, Bonte B, et al. Acute pain assessment and opioid prescribing protocol. Institute for Clinical Systems Improvement. 2014. https://www.icsi.org 61. VA/DoD Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guidelines for the management of opioid therapy for chronic pain. 2003. Contract number: V101 (93). 62. Food and Drug Administration. FDA approves first generic naloxone nasal spray to treat opioid overdose. FDA News Release. April 19, 2019. 63. Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review. Ann Int Med 2017;167(3):181-191. 64. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: Evidence and recommendations for everyday practice. Mayo Clin Proc 2015;90(6):828-842. 65. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. 2019. https://www.fda.gov/Drugs/DrugSafety/ucm635038.htm 66. Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open 2023;6(8):e2327488. doi: 10.1001/jamanetworkopen.2023.27488 67. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. 68. Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants. 2017. www.fda.gov/Drugs/DrugSafety/ucm575307.htm 69. Binswanger IA, Glanz JM. Potential risk window for opioid overdose related to treatment with extended-release injectable naltrexone. Drug Saf 2018;41(10):979-980. 70. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatr 2015;23(2):63-75. 71. Walters SM, Liu W, Lamuda P, Huh J, Brewer R, Johnson O, Bluthenthal RN, Taylor B, Schneider JA. A national portrait of public attitudes toward opioid use in the US: a latent class analysis. Int J Environ Res Public Health 2023, Mar 2;20(5):4455. doi: 10.3390/ ijerph20054455. PMID: 36901465; PMCID: PMC10001548. 72. Food and Drug Administration. FDA approves first generic naloxone nasal spray to treat opioid overdose. FDA News Release. April 19, 2019. 73. Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addict 2012;107(9):1621-1629. 74. Schwartz RP. When added to opioid agonist treatment, psychosocial interventions do not further reduce the use of illicit opioids: a comment on Dugosh et al. J Addict Med 2016;10(4):283-285. 75. Substance Abuse and Mental Health Services Administration. Buprenorphine. 2019. https://www.samhsa.gov/medication-assisted- treatment/treatment/buprenorphine 76. Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis - buprenorphine myths and realities. N Engl J Med 2018;379(1):1-4. 77. Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend 2021 Apr 1;221:108627. doi: 10.1016/j.drugalcdep.2021.108627. Epub 2021 Feb 16. PMID: 33621805; PMCID: PMC8026666. 78. Dooley J, Gerber-Finn L, Antone I, Guilfoyle J, Blakelock B, Balfour-Boehm J, Hopman WM, Jumah N, Kelly L. Buprenorphine- naloxone use in pregnancy for treatment of opioid dependence: Retrospective cohort study of 30 patients. Can Fam Physician 2016 Apr;62(4):e194-200. PMCID: PMC4830675. 79. Metz VE, Brown QL, Martins SS, Palamar JJ. Characteristics of drug use among pregnant women in the United States: Opioid and non- opioid illegal drug use. Drug Alc Depend 2018;183:261-266.
Page 1 Page 2 Page 3Powered by FlippingBook